Satoshi Hokari

Satoshi Hokari

Auto-generated profile, based on publicly available information

Satoshi Hokari

Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8520, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2017 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
AKAkihiro Katsura
Akihiro Katsura
YTYusuke Tamura
Yusuke Tamura
SHSatoshi Hokari
Satoshi Hokari
MHMayumi Harada
Mayumi Harada
MMMasato Morikawa
Masato Morikawa
DKDaizo Koinuma
Daizo Koinuma
Zinc finger E‐box binding protein 1 (ZEB1) and ZEB2 induce epithelial‐mesenchymal transition (EMT) and enhance cancer progression. However, the global view of transcriptional regulation by ZEB1 and ZEB2 is yet to be elucidated. Here, we identified a ZEB1‐regulated inflammatory phenotype in breast cancer cells using chromatin immunoprecipitation sequencing and RNA sequencing, followed by gene set enrichment analysis (GSEA) of ZEB1‐bound genes. Knockdown of ZEB1 and/or ZEB2 resulted in the downregulation of genes encoding inflammatory cytokines related to poor prognosis in patients with cancer, including IL6 and IL8, therefore suggesting that ZEB1 and ZEB2 have similar functions in terms of the regulation of production of inflammatory cytokines. Antibody array and ELISA experiments confirmed that ZEB1 controlled the production of the IL‐6 and IL‐8 proteins. The secretory proteins regulated by ZEB1 enhanced breast cancer cell proliferation and tumor growth. ZEB1 expression in breast cancer cells also affected the growth of fibroblasts in cell culture, and the accumulation of myeloid‐derived suppressor cells in tumors in vivo. These findings provide insight into the role of ZEB1 in the progression of cancer, mediated by inflammatory cytokines, along with the initiation of EMT.

29 May 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
NKNatsumi Kawasaki
Natsumi Kawasaki
TMToshiki Miwa
Toshiki Miwa
SHSatoshi Hokari
Satoshi Hokari
TSTsubasa Sakurai
Tsubasa Sakurai
KOKazuho Ohmori
Kazuho Ohmori
DKDaizo Koinuma
Daizo Koinuma
Long noncoding RNAs are involved in a variety of cellular functions. In particular, an increasing number of studies have revealed the functions of long noncoding RNA in various cancers; however, their precise roles and mechanisms of action remain to be elucidated. NORAD, a cytoplasmic long noncoding RNA, is upregulated by irradiation and functions as a potential oncogenic factor by binding and inhibiting Pumilio proteins (PUM1/PUM2). Here, we show that NORAD upregulates transforming growth factor‐β (TGF‐β) signaling and regulates TGF‐β‐induced epithelial‐to‐mesenchymal transition (EMT)‐like phenotype, which is a critical step in the progression of lung adenocarcinoma, A549 cells. However, PUM1 does not appear to be involved in this process. We thus focused on importin β1 as a binding partner of NORAD and found that knockdown of NORAD partially inhibits the physical interaction of importin β1 with Smad3, inhibiting the nuclear accumulation of Smad complexes in response to TGF‐β. Our findings may provide a new mechanism underlying the function of NORAD in cancer cells.

1 June 2017 in Sleep Medicine
Verified
Journal Article
Closed access
YOYasuyoshi Ohshima
Yasuyoshi Ohshima
HNHideaki Nakayama
Hideaki Nakayama
NMNaho Matsuyama
Naho Matsuyama
SHSatoshi Hokari
Satoshi Hokari
TSTakuro Sakagami
Takuro Sakagami
TSTakayoshi Shimohata
Takayoshi Shimohata

29 November 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
MSMasaaki Sakuraya
Masaaki Sakuraya
HOHiromu Okano
Hiromu Okano
TMTomoyuki Masuyama
Tomoyuki Masuyama
SKShunsuke Kimata
Shunsuke Kimata
SHSatoshi Hokari
Satoshi Hokari
Background: Although non-invasive respiratory management strategies have been implemented to avoid intubation, patients with de novo acute hypoxaemic respiratory failure (AHRF) are high risk of treatment failure. In the previous meta-analyses, the effect of non-invasive ventilation was not evaluated according to ventilation modes in those patients. Furthermore, no meta-analyses comparing non-invasive respiratory management strategies with invasive mechanical ventilation (IMV) have been reported. We performed a network meta-analysis to compare the efficacy of non-invasive ventilation according to ventilation modes with high-flow nasal oxygen (HFNO), standard oxygen therapy (SOT), and IMV in adult patients with AHRF. Methods: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and Ichushi databases were searched. Studies including adults with AHRF and randomized controlled trials (RCTs) comparing two different respiratory management strategies (continuous positive airway pressure (CPAP), pressure support ventilation (PSV), HFNO, SOT, or IMV) were reviewed. Results: We included 25 RCTs (3,302 participants: 27 comparisons). Using SOT as the reference, CPAP (risk ratio [RR] 0.55; 95% confidence interval [CI] 0.31–0.95; very low certainty) was associated significantly with a lower risk of mortality. Compared with SOT, PSV (RR 0.81; 95% CI 0.62–1.06; low certainty) and HFNO (RR 0.90; 95% CI 0.65–1.25; very low certainty) were not associated with a significantly lower risk of mortality. Compared with IMV, no non-invasive respiratory management was associated with a significantly lower risk of mortality, although all certainties of evidence were very low. The probability of being best in reducing short-term mortality among all possible interventions was higher for CPAP, followed by PSV and HFNO; IMV and SOT were tied for the worst (surface under the cumulative ranking curve value: 93.2, 65.0, 44.1, 23.9, and 23.9, respectively). Conclusions: When performing non-invasive ventilation among patients with de novo AHRF, it is important to avoid excessive tidal volume and lung injury. Although pressure support is needed for some of these patients, it should be applied with caution because this may lead to excessive tidal volume and lung injury. Trial registration protocols.io (Protocol integer ID 49375, April 23, 2021). https://doi.org/10.17504/protocols.io.buf7ntrn.

29 November 2019 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
SHSatoshi Hokari
Satoshi Hokari
YTYusuke Tamura
Yusuke Tamura
AKAtsushi Kaneda
Atsushi Kaneda
AKAkihiro Katsura
Akihiro Katsura
MMMasato Morikawa
Masato Morikawa
DKDaizo Koinuma
Daizo Koinuma
Thyroid transcription factor‐1 (TTF‐1, encoded by the NKX2‐1 gene) is highly expressed in small‐cell lung carcinoma (SCLC) and lung adenocarcinoma (LADC), but how its functional roles differ between SCLC and LADC remains to be elucidated. Here, we compared the genome‐wide distributions of TTF‐1 binding regions and the transcriptional programs regulated by TTF‐1 between NCI‐H209 (H209), a human SCLC cell line, and NCI‐H441 (H441), a human LADC cell line, using chromatin immunoprecipitation‐sequencing (ChIP‐seq) and RNA‐sequencing (RNA‐seq). TTF‐1 binding regions in H209 and H441 cells differed by 75.0% and E‐box motifs were highly enriched exclusively in the TTF‐1 binding regions of H209 cells. Transcriptome profiling revealed that TTF‐1 is involved in neuroendocrine differentiation in H209 cells. We report that TTF‐1 and achaete‐scute homolog 1 (ASCL1, also known as ASH1, an E‐box binding basic helix–loop–helix transcription factor, and a lineage‐survival oncogene of SCLC) are coexpressed and bound to adjacent sites on target genes expressed in SCLC, and cooperatively regulate transcription. Furthermore, TTF‐1 regulated expression of the Bcl‐2 gene family and showed antiapoptotic function in SCLC. Our findings suggest that TTF‐1 promotes SCLC growth and contributes to neuroendocrine and antiapoptotic gene expression by partly coordinating with ASCL1.

1 December 2021 in Brain Research Bulletin
Verified
Journal Article
Closed access
RMRika Moriya
Rika Moriya
MKMitsuko Kanamaru
Mitsuko Kanamaru
NONaoki Okuma
Naoki Okuma
AYAkira Yoshikawa
Akira Yoshikawa
KTKenji F. Tanaka
Kenji F. Tanaka
MIMasahiko Izumizaki
Masahiko Izumizaki